F-Prime Capital β 2023 Investments
12 investments dated 2023 Β· listed companies and verified rows first Β· show all
Neumora is a clinical research company developing investigational medications, with a focus on conducting clinical trials to obtain regulatory approval and make treatments available to patients.
BiotechDeep TechDigital HealthMedical DevicesWatertown, US
Joshua Pinto(Executive Officer)Tamara Tompkins(Executive Officer)Kari Stefansson(Director)Maykin Ho(Director)Alaa Halawa(Director)
BoardKristina Burow(Director)in
Board seatStacie WeningerΒ· per SEC Form D
Co-investorsARCH Venture PartnersCatalio Capital Management, LPK2 HealthVenturesMercury FundPremier PartnersSoftBank Vision Fund+1 more
Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.
BiotechHealthtech
Lyn Baranowski(CEO)in
Co-investorsAndera PartnersCatalio Capital Management, LPInVivium CapitalNorwest Venture PartnersRiverVest Venture PartnersSR One Capital Management+7 more
1upHealth provides a FHIR-first health data platform that helps health plans and payers acquire, manage, and exchange healthcare data, including automating prior authorization, member data access, and provider directories.
Data & InfrastructureDigital HealthHealthtechBoston, US
Ritwik Sahu(Executive Officer, Director)Ricky Sahu(Founder)inJoseph Gagnon(Director)
BoardVictor Echevarria(Director)inDavid Jegan(Director)T. Scott Law, Jr.(Director)
Board seatDavid JegenΒ· per SEC Form D
Co-investorsEniac VenturesJackson Square VenturesMeridian Street CapitalSixth StreetSocial Leverage
CHARM is a biotech company developing a next-generation menin inhibitor for acute myeloid leukemia (AML), designed to address resistance seen with first-generation approaches.
AI & Machine LearningBiotechHealthtechLondon
Gary Glick(Director)Lakshyaditya Singh Aithani(Executive Officer, Director)Muzammil Mansuri(Director)
BoardRishi Gupta(Director)
Board seatMuz MansuriNihal SinhaΒ· per SEC Form D
Co-investorsNew Enterprise Associates (NEA)OrbiMedSR One Capital ManagementAxial VCNVentures
Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment.
BiotechHealthtechMedical DevicesBoston, US
Board seatStephen KnightΒ· per SEC Form D
Co-investors5AM VenturesAju IB Invesment CorporationCatalio Capital Management, LPDelos CapitalSolasta VenturesBioluminescence Ventures
Seattle, US
Ronald Seubert(Executive Officer, Director, Promoter)Evan Castiglia(Executive Officer)Joseph Victor(Executive Officer, Director)Frank Witney(Director)Eric Kaldjian(Executive Officer)
BoardRobert Shepler(Director)in
Board seatRobert WeisskoffΒ· per SEC Form D
Co-investors5AM VenturesArboretum VenturesSofinnova VenturesTelegraph Hill Partners
Tradier offers REST-based APIs and trading platforms providing equity, options, and futures trading, account management, market data, and brokerage services for individual developers and businesses.
FintechSaaSCharlotte, US
Dan Raju(Executive Officer, Director)inRobert Kopple(Director)Alec Petro(Director)Peter Laptewicz(Executive Officer, Director)in
Board seatDavid JegenΒ· per SEC Form D
Co-investorsDevonshire Investors
Zus provides a platform that removes data waste in healthcare, enabling developers, clinicians, and operators to innovate in patient and care team experience without building underlying infrastructure.
Cloud ComputingData & InfrastructureDigital HealthHealthtechWatertown, US
Jonathan Bush(CEO)inTravis Smith(Executive Officer)
BoardSteven Fisher(Director)Fay Rotenberg(Director)Julie Yoo(Director)inBenjamin Silver(Director)
Board seatCarl ByersΒ· per SEC Form D Β· $40M raise Β· filed Mar 2023
Co-investorsAdvection Growth CapitalAndreessen HorowitzJAZZ Venture PartnersMartin VenturesMaverick Ventures
Doceree offers a software platform for pharmaceutical brand teams, positioned as a single "system of work" that unifies market research, HCP targeting, media planning, measurement, CRM, and MLR workflows in place of fragmented tools.
AdTechDigital HealthMarketing TechSaaSShort Hills, US
Harshit Jain(Founder & Global CEO)inKamya Elawadhi(Co-Founder & President)inPulkit Jain(VP - Finance & Investments)Vijay Adapala(Chief Business Development Officer)inThomas Shea(Chief Revenue Officer, AI and Patient Affordability Solutions)inYesh Srinivasan(Chief AI Officer)
Co-investorsAlkemi Growth CapitalEight Roads Ventures
Eleos develops AI-powered software that helps behavioral health clinicians deliver more effective care through data measurement and personalization.
AI & Machine LearningDigital HealthHealthtechMental HealthCambridge, US
Alon Joffe(Chief Executive Officer)inDror Zaide(Chief Revenue Officer)inAlon Rabinovich(Chief Technology Officer)inDenny Morrison(Chief Clinical Officer)inRaz Karmi(Chief Information Security Officer)inNoam Cohen(VP of R&D)in
Co-investorsaMoonArkin CapitalGreenfield PartnersLool VenturesMaccabee VenturesMenlo Ventures+2 more
ARTBIO develops alpha radioligand therapies (ARTs) for cancer treatment, designing target-and-molecule combinations intended to kill tumors while sparing healthy tissue.
BiotechHealthtechMedical DevicesOslo, NO
Roy Larsen(Scientific Founder)Γyvind Bruland(Scientific Founder)Jonathan Freeman(Interim CEO)Margaret Yu(Chief Medical Officer)Philippe Dasse(Chief Technical Officer)Amra Demirovic(Chief Human Resources Officer)
Co-investorsB Capital GroupB4 CapitalAlexandriaB CapitalQatar Investment AuthoritySofinnova Ventures+1 more
Warmly is an AI-powered sales prospecting and outreach platform that helps companies identify and engage with qualified leads, reducing the need for traditional Sales Development Representative services.
AI & Machine LearningEnterprise SoftwareSales TechSan Francisco, US
Max Greenwald(Founder)inCarina Boo(Founder)inAlan Zhao(Founder)in
Co-investorsFelicis VenturesMaven VenturesNFXRTP GlobalY CombinatorEarl Grey Capital+3 more
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.